Lusutrombopag
Lusutrombopag
Definition
An orally available thrombopoietin (TPO) receptor (TPOR; MPL) agonist, with potential megakaryopoiesis stimulating activity. Upon administration, lusutrombopag binds to and interacts with the transmembrane domain of human TPO receptor expressed on megakaryocytes, which leads to the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells. This increases the production of platelets and may prevent or treat thrombocytopenia in patients with chronic liver disease. TPOR is a cytokine receptor and member of the hematopoietic receptor superfamily.
Also known as LUSUTROMBOPAG, Mulpleo, Mulpleta — per NCIT
Also identified as
- ATC B02BX07 per RXNORM
- NCIT NCIT:C166948 per NCIT
- SCTID 773263005 per RXNORM
- SCTID 773265003 per RXNORM
- UNII 6LL5JFU42F per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Thrombocytopenia | may treat | MEDRT · Public domain (U.S. Government work) |